Hepatic encephalopathy syndromes

Area of Science:

• Hepatology
• Neuroscience
• Metabolic Disorders

Background:

• Hepatic encephalopathy (HE) is a neuropsychiatric complication linked to acute and chronic liver failure.
• HE presents a spectrum from minimal (subclinical) to overt forms, impacting cognitive function.
• Brain metabolite alterations, including myo-inositol depletion and glutamine accumulation, are key diagnostic indicators for minimal HE.

Purpose of the Study:

• To review diagnostic methods for minimal hepatic encephalopathy.
• To explore therapeutic strategies targeting ammonia metabolism in HE.
• To evaluate the efficacy of L-ornithine-L-aspartate in HE treatment.

Main Methods:

• Review of psychometric and electrophysiological tests for minimal HE diagnosis.
• Analysis of brain metabolite changes (myo-inositol, glutamine) for diagnostic sensitivity and specificity.
• Assessment of positron emission tomography in studying brain ammonia metabolism.
• Evaluation of ammonia-lowering treatments including diet, lactulose, antibiotics, sodium benzoate, and L-ornithine-L-aspartate.

Main Results:

• Minimal HE diagnosis is aided by psychometric and electrophysiological tests.
• Brain metabolite changes offer sensitive and specific diagnostic markers for minimal HE.
• L-ornithine-L-aspartate provides substrates for ammonia detoxification via ureagenesis and glutamine synthesis.
• Recent trials indicate L-ornithine-L-aspartate is effective in treating HE.

Conclusions:

• Metabolite analysis is a sensitive and specific diagnostic approach for minimal hepatic encephalopathy.
• Modifying ammonia metabolism is central to HE treatment.
• L-ornithine-L-aspartate demonstrates effectiveness in managing hepatic encephalopathy.